Baseline biomarkers including BRAF mutation status, serum lactate dehydrogenase levels, PD-L1 expression, and tumor mutation burden were correlated with progression-free survival (PFS).<h4>Results</h4>Treatment outcomes were analyzed in 54 sequential patients. Here, BRAF is linked to neoplasm.